The Circulation Journal Official Impact Factor and the Most Frequently Cited Papers in 2021
論文ID: CJ-66-0208
この記事には本公開記事があります。
詳細
論文ID: CJ-66-0208
Dear Colleagues,
On behalf of the Circulation Journal , I would like to report its official 2021 Impact Factor and the related information in detail as follows:
I would like to report that Circulation Journal has earned an official 2021 Impact Factor of 3.350 (2020: 2.993). The official ranking places Circulation Journal the 72nd among the 143 journals in the Cardiac & Cardiovascular Systems category in 2021 JCR Science Edition (74th among the 142 journals in 2020). I would like to ask readers to use Circulation Journal papers as reference papers in your future submission of manuscripts to any journals.
The following papers, published in 2019–2020, are the top 31 most frequently cited papers in 2021, thereby substantially contributing to the 2021 Impact Factor of the Journal. Numbers in the parenthesis denote the number of citations in 2021.
1. (119) Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al; the Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. Circ J 2019; 83: 2084–2184.
2. (70) Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al; the Japanese Circulation Society Joint Working Group. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J 2019; 83: 1085–1196.
3. (41) Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M, et al; the Japanese Circulation Society Joint Working Group. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis: Digest version. Circ J 2019; 83: 2329–2388.
(41) Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J 2020; 84: 831–865.
5. (24) Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, et al; the Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group. Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017). Circ J 2019; 83: 842–945.
6. (22) Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, et al; the Japanese Circulation Society Joint Working Group. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J 2020; 84: 1348–1407.
7. (19) Nakatani S, Ohara T, Ashihara K, Izumi C, Iwanaga S, Eishi K, et al; the Japanese Circulation Society Joint Working Group. JCS 2017 guideline on prevention and treatment of infective endocarditis. Circ J 2019; 83: 1767–1809.
(19) Murata N, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al; the SAKURA AF Registry Investigators. Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF Registry. Circ J 2019; 83: 727–735.
9. (18) Hayashi T, Yamashita T, Watanabe H, Kami K, Yoshida N, Tabata T, et al. Gut microbiome and plasma microbiome-related metabolites in patients with decompensated and compensated heart failure. Circ J 2019; 83: 182–192.
(18) Kondo T, Nakano Y, Adachi S, Murohara T. Effects of tobacco smoking on cardiovascular disease. Circ J 2019; 83: 1980–1985.
(18) Izumi C, Eishi K, Ashihara K, Arita T, Otsuji Y, Kunihara T, et al; the Japanese Circulation Society Joint Working Group. JCS/JSCS/JATS/JSVS 2020 guidelines on the management of valvular heart disease. Circ J 2020; 84: 2037–2119.
12. (17) Benincasa G, Marfella R, Della Mura N, Schiano C, Napoli C. Strengths and opportunities of network medicine in cardiovascular diseases. Circ J 2020; 84: 144–152.
13. (15) Tada H, Okada H, Nomura A, Yashiro S, Nohara A, Ishigaki Y, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J 2019; 83: 1917–1924.
(15) Xie Y, You Q, Wu C, Cao S, Qu G, Yan X, et al. Impact of cardiovascular disease on clinical characteristics and outcomes of coronavirus disease 2019 (COVID-19). Circ J 2020; 84: 1277–1283.
15. (14) Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, et al; the JCS Joint Working Group. JCS 2017 guideline on management of vasculitis syndrome: Digest version. Circ J 2020; 84: 299–359.
(14) Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the treatment of cardiovascular diseases. Circ J 2019; 83: 252–260.
(14) Li T, Gu J, Yang O, Wang J, Wang Y, Kong J. Bone marrow mesenchymal stem cell-derived exosomal miRNA-29c decreases cardiac ischemia/reperfusion injury through inhibition of excessive autophagy via the PTEN/Akt/mTOR signaling pathway. Circ J 2020; 84: 1304–1311.
18. (12) Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al; the Japanese Circulation Society Joint Working Group. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 2020; 84: 1610–1671.
(12) Kusunose K, Haga A, Abe T, Sata M. Utilization of artificial intelligence in echocardiography. Circ J 2019; 83: 1623–1629.
(12) Tsutsui H, Momomura S, Yamashina A, Shimokawa H, Kihara Y, Saito Y, et al; the J-SHIFT Study Investigators. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure: J-SHIFT study. Circ J 2019; 83: 2049–2060.
(12) Izawa H, Yoshida T, Ikegame T, Izawa KP, Ito Y, Okamura H, et al; the Japanese Association of Cardiac Rehabilitation Standard Cardiac Rehabilitation Program Planning Committee. Standard cardiac rehabilitation program for heart failure. Circ J 2019; 83: 2394–2398.
22. (11) Kario K, Yamamoto E, Tomita H, Okura T, Saito S, Ueno T, et al; the SYMPLICITY HTN-Japan Investigators. Sufficient and persistent blood pressure reduction in the final long-term results from SYMPLICITY HTN-Japan: Safety and efficacy of renal denervation at 3 years. Circ J 2019; 83: 622–629.
(11) Yamagishi S. Role of advanced glycation endproduct (AGE)-receptor for advanced glycation endproduct (RAGE) axis in cardiovascular disease and its therapeutic intervention. Circ J 2019; 83: 1822–1828.
(11) Wong CK, Luk HK, Lai WH, Lau YM, Zhang RR, Wong AC, et al. Human-induced pluripotent stem cell-derived cardiomyocytes platform to study SARS-CoV-2 related myocardial injury. Circ J 2020; 84: 2027–2031.
25. (10) Sato K, Sakamoto K, Hashimoto Y, Hanzawa K, Sueta D, Kojima S, et al; the KEEP Project. Risk factors and prevalence of deep vein thrombosis after the 2016 Kumamoto earthquakes. Circ J 2019; 83: 1342–1348.
26. (9) Yamaguchi O. Autophagy in the heart. Circ J 2019; 83: 697–704.
(9) Nakamura K, Murry CE. Function follows form: A review of cardiac cell therapy. Circ J 2019; 83: 2399–2412.
(9) Okamoto H, Kume T, Yamada R, Koyama T, Tamada T, Imai K, et al. Prevalence and clinical significance of layered plaque in patients with stable angina pectoris: Evaluation with histopathology and optical coherence tomography. Circ J 2019; 83: 2452–2459.
(9) Noda T, Nishigaki K, Minatoguchi S. Safety and efficacy of human muse cell-based product for acute myocardial infarction in a first-in-human trial. Circ J 2020; 84: 1189–1192.
(9) Yoshioka N, Takagi K, Morishima I, Morita Y, Uemura Y, Inoue Y, et al. Influence of preadmission frailty on short- and mid-term prognoses in octogenarians with ST-elevation myocardial infarction. Circ J 2020; 84: 109–118.
(9) Hu YF, Cheng WH, Hung Y, Lin WY, Chao TF, Liao JN, et al. Management of atrial fibrillation in COVID-19 pandemic. Circ J 2020; 84: 1679–1685.
The following papers are the top 38 most frequently cited papers among the 7,738 papers published in the Circulation Journal (2002–2021). Numbers in the parenthesis denote the number of citations.
1. (1323) Matsuzawa Y, Nakamura T, Takahashi M, Ryo M, Inoue S, Ikeda Y, et al. New criteria for ‘obesity disease’ in Japan. Circ J 2002; 66: 987–992. (Review)
2. (558) Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975–981.
3. (548) Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213–220. (Review)
4. (530) Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411–418. (Review)
5. (460) Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; on behalf of the J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF Study. Circ J 2012; 76: 2104–2111.
6. (429) Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818–826. (Review)
7. (385) Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010; 74: 2257–2262. (Review)
8. (345) Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J 2009; 73: 595–601. (Review)
9. (335) Inoue H, Atarashi H, Kamakura S, Koretsune Y, Kumagai K, Mitamura H, et al; JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997–2021.
10. (271) Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007; 71: 536–539.
11. (266) Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928–933.
(266) Ogawa H, Akasaka T, Hattori R, Inoue T, Kawashima S, Kawasuji M, et al; JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013): Digest version. Circ J 2014; 78: 2779–2801.
13. (259) Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79: 495–502. (Review)
14. (249) Ando J, Yamamoto K. Vascular mechanobiology: Endothelial cell responses to fluid shear stress. Circ J 2009; 73: 1983–1992. (Review)
15. (236) Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al; for the JCARE-CARD Investigators. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893–1900.
16. (233) Ueyama T, Kasamatsu K, Hano T, Yamamoto K, Tsuruo Y, Nishio I. Emotional stress induces transient left ventricular hypocontraction in the rat via activation of cardiac adrenoceptors: A possible animal model of ‘Takotsubo’ cardiomyopathy. Circ J 2002; 66: 712–713.
(233) Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al; the Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. Circ J 2019; 83: 2084–2184.
18. (229) Tomiyama H, Yamashina A. Non-invasive vascular function tests: Their pathophysiological background and clinical application. Circ J 2010; 74: 24–33. (Review)
19. (219) Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006; 70: 1437–1442.
20. (218) Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2012; 76: 485–488.
21. (216) Kawai S, Kitabatake A, Tomoike H; Takotsubo Cardiomyopathy Study Group. Guidelines for diagnosis of Takotsubo (ampulla) cardiomyopathy. Circ J 2007; 71: 990–992.
22. (213) Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684–1692.
23. (211) Swift DL, Lavie CJ, Johannsen NM, Arena R, Earnest CP, O’Keefe JH, et al. Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention. Circ J 2013; 77: 281–292. (Review)
24. (202) Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J 2008; 72: 598–604.
25. (198) Ogura R, Hiasa Y, Takahashi T, Yamaguchi K, Fujiwara K, Ohara Y, et al. Specific findings of the standard 12-lead ECG in patients with ‘Takotsubo’ cardiomyopathy: Comparison with the findings of acute anterior myocardial infarction. Circ J 2003; 67: 687–690.
26. (197) Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: Approach to therapy. Circ J 2011; 75: 1287–1296. (Review)
27. (196) Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J 2005; 69: 815–822.
28. (194) Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597–607. (Review)
29. (192) Takigiku K, Takeuchi M, Izumi C, Yuda S, Sakata K, Ohte N, et al. Normal range of left ventricular 2-dimensional strain: Japanese ultrasound speckle tracking of the left ventricle (JUSTICE) study. Circ J 2012; 76: 2623–2632.
30. (191) Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ J 2008; 72: 489–491.
31. (187) Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, et al. Pulse wave velocity predicts cardiovascular mortality: Findings from the Hawaii-Los Angeles-Hiroshima study. Circ J 2005; 69: 259–264.
(187) Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J 2013; 77: 1111–1122. (Review)
33. (183) Ando M, Fukuda I, Ito M, Kobayashi T, Masuda M, Miyahara Y, et al; JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009): Digest version. Circ J 2011; 75: 1258–1281.
34. (180) Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: A pilot study. Circ J 2012; 76: 1750–1760.
35. (179) Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, et al. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 2013; 77: 705–711.
36. (178) Ogawa H, Akasaka T, Hattori R, Kawashima S, Kawasuji M, Kimura K, et al; JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): Digest version. Circ J 2010; 74: 1745–1762.
37. (176) Ehara M, Surmely JF, Kawai M, Katoh O, Matsubara T, Terashima M, et al. Diagnostic accuracy of 64-slice computed tomography for detecting angiographically significant coronary artery stenosis in an unselected consecutive patient population: Comparison with conventional invasive angiography. Circ J 2006; 70: 564–571.
(176) Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia: Primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1087–1095.
The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.
